Finoriq research workspace
ACCURAY INC (ARAY) Historical Metrics
Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery. Review ARAY valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
- Company
- ACCURAY INC (ARAY)
- Ticker
- ARAY
- Market Cap
- $29.8M
- Latest Price
- $0.2505
- Industry
- Medical Devices
ACCURAY INC (ARAY) Current Valuation Metrics
Static valuation preview for ACCURAY INC (ARAY). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 0.07x | Revenue | TTM Q3 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | -149.5% | Net Income | TTM Q3 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -61.9% | Operating Cash Flow | TTM Q3 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 0.74x | Stockholders' Equity | Q3 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.